Sanofi

Dr Reddy's to introduce Sanofi's novel drug in India

The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants

Sanofi gets CDSCO nod for Beyfortus India

Beyfortus is used for the prevention of Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants.

Sanofi to invest Euro 400 million in its Hyderabad GCC by 2030

Madeliene Roach, Executive Vice President, Business Operations, Sanofi said in a press conference that over the next two years, this GCC will expand to host up to approximately 2,600 employees, making it the largest of Sanofi's four global hubs.

Lupin arm completes acquisition of two brands from Sanofi

Lupin Atlantis Holdings SA has completed the acquisition of Aarane in Germany and Nalcrom in Canada and the Netherlands, along with the associated trademark rights, from Sanofi, the Mumbai-based drug maker said in a statement.

Novavax shares soar on license deal with Sanofi at lofty valuation

The cash infusion is likely to strengthen the balance sheet of the vaccine maker, whose shares lost more than 98% of their value since the early days of pandemic as it struggled to get its vaccine to the market in a timely manner

Sanofi introduces diabetes drug Soliqua in India

The company introduced the medication after receiving the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) earlier last year.

Dr Reddy's inks distribution agreement for Sanofi vaccines in India

MV Ramana, chief executive officer, branded markets (India and emerging markets), Dr. Reddy’s, said the portfolio will give Dr Reddy’s a solid presence in the vaccine segment.

Sanofi ties up with Emcure to broaden reach of cardiovascular brands

Sanofi India's concerned employees will have the opportunity to work at Emcure, it added.

Lupin to acquire established products in Europe, Canada from Sanofi for Rs 91 cr

Lupin Atlantis Holdings SA, Switzerland, a wholly-owned subsidiary of the company, has signed an asset purchase agreement with Sanofi, a French multinational pharmaceutical and healthcare company, for the purpose, Lupin said in a regulatory filing.